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CC BY-NC-ND license (http://creativeAbstract Objective: The purpose of this review was to evaluate the effectiveness of tradi-
tional Chinese medicine for activating blood circulation and detoxifying (ABCD) in patients
with unstable angina pectoris.
Methods: We performed an electronic literature search of six medical databases for relevant
articles published up to December 2014. Randomized controlled trials that compared ABCD
Chinese medicine (alone or alongside conventional drugs) with conventional drugs or other Chi-
nese medicines alone were included. A meta-analysis was performed for the following
outcome measures: reduction of angina symptoms, electrocardiogram improvement, blood
lipid levels, inflammatory factor levels, and plasma fibrinogen levels.
Results: In total, 11 moderate- to low-quality studies involving 686 patients were included.
The evidence indicated that ABCD Chinese medicine exhibited superior effectiveness in
relieving angina symptoms compared with conventional drugs [relative risk, 1.23; 95%circulation and detoxifying; UAP, unstable angina pectoris; RCTs, randomized controlled trials; RAS,
electrocardiogram; FIB, fibrinogen; CI, confidence interval; RR, relative risk; ACS, acute coronary
hs-CRP, high-sensitivity C-reactive protein; CBM, Chinese Biological Medicine; CNKI, China National
e Scientific Journal database; WFDP, WanFang Digital Periodicals; WMDs, weighted mean differences;
, total duration of angina attacks in 24 h; SRRN, stopping or reducing rate of nitroglycerin; TC, total
igh-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol (LDL-C); TNFa, tumor
protein.
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72 Y. Zhang et al.confidence interval, 1.05e1.44]; however, electrocardiogram improvement was not very sig-
nificant (relative risk, 1.21; 95% confidence interval, 0.91e1.62). Moreover, ABCD Chinese
medicine exhibited superior anti-inflammatory, anticoagulant, and lipid-lowering effects
compared with other medicines.
Conclusions: Within the methodological limitations of the included studies, our results suggest
that ABCD Chinese medicine is beneficial for the treatment of unstable angina pectoris.
ª 2015 Beijing University of Chinese Medicine. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).Introduction
Although therapeutic strategies for coronary heart diseases
have greatly advanced and mortality rates have decreased
in Western countries over the past few decades,1 mortality
and morbidity associated with these diseases are still
increasing in China, where a large number of patients are
diagnosed with acute coronary syndrome (ACS). ACS in-
cludes unstable angina pectoris (UAP), non-ST-elevated
myocardial infarction (MI), and ST-elevated MI, which
describe different degrees of myocardial ischemic states.2
UAP is the most common clinical presentation of ACS.
Conventional medications for UAP include aspirin,
angiotensin-converting enzyme inhibitors, beta-blockers,
calcium antagonists, and nitrates.3 However, all these
drugs may have undesirable effects. For example, aspirin
can potentially increase the incidence of hemorrhage and
some patients have acquired resistance to the drug.
Traditional Chinese medicine has become a popular
treatment for UAP. According to modern medical theory,
platelet activation, thrombosis, and inflammation are
central to UAP pathogenesis. In contrast, according to
traditional Chinese medicine, blood stasis is at the core of
UAP development. If blood stasis is not eliminated, it re-
sults in the production of toxins over time. Therefore,
numerous modern medical studies have been conducted on
the use of traditional Chinese medicine for activating blood
circulation and detoxifying (ABCD). Basic studies have
revealed that ABCD can decrease tissue damage and the
expression of inflammation-related factors in the rat model
of carotid artery thrombosis,4 inhibit the nuclear factor
kappa B pathway and decrease matrix metalloproteinase-9
in the aorta of apolipoprotein E knockout mice,5 decrease
serum high-sensitivity C-reactive protein (hs-CRP) levels,6
decrease apoptosis and oxidative damage to umbilical
vein endothelial cells induced by oxidized low-density li-
poprotein,7 and inhibit coagulation and platelet activation
in a rat model of acute MI.8
In clinical practice, ABCD Chinese medicine has been
found to exhibit add-on effects in UAP patients; it can
enhance the effectiveness of conventional medicine in
relieving angina symptoms,9e12 decrease the dosage of
nitroglycerin, and minimize adverse effects.13 However,
evidence supporting or disproving these cardiovascular
protective effects has not been systematically reviewed.
We therefore conducted this study to systematically and
objectively evaluate the clinical efficacy of ABCD Chinese
medicine for UAP based on a comprehensive understandingof previous studies and meta-analyses of randomized
controlled trials (RCTs).
Methods
Search strategy
We performed an electronic literature search using the
following databases: PubMed (1989eDecember 2014), Web
of Science (1990eDecember 2014), Chinese Biological
Medicine (CBM; 1990eDecember 2014), China National
Knowledge Infrastructure (CNKI; 1989eDecember 2014),
Chinese Scientific Journal (VIP; 1989eDecember 2014), and
WanFang Digital Periodicals (WFDP; 1989eDecember 2014).
There were no language restrictions. We used the following
English search terms alone or in combination: “traditional
Chinese medicine,” “activating blood circulation and
detoxifying,” “unstable angina pectoris,” “randomized
controlled trials,” “controlled trials,” and “randomly.”
Chinese search terms included generic names for UAP
(“Bu_wen_ding_xing_xin_jiao_tong”), ABCD (Huo_xue_
jie_du or Hua_yu_jie_du), frequently used herbal formulae
for ABCD (Wu_wei_xiao_du_yin, si_miao_yong_an_tang or
Xian_fang_huo_ming_yin), and randomized (Sui_ji).
Study selection
The inclusion criteria for studies were as follows: RCTs;
inclusion of patients diagnosed with UAP according to
accepted criteria; comparison of ABCD Chinese medicine as
an intervention or co-intervention (alongside conventional
drugs for UAP) with no treatment, placebo, other types of
Chinese medicines, or conventional drugs; measurement of
the effectiveness of ABCD Chinese medicine for UAP by a
reduction in angina symptoms (RAS), electrocardiogram
(ECG) improvement, and laboratory indices.14
Data extraction and methodological quality
assessment
Two investigators (Ying Zhang and Xiaojuan Ma) evaluated
all studies and independently extracted relevant data from
each using a structured table. To resolve any disputes, a
third investigator (Dazhuo Shi) was consulted.14 The
following data were extracted: number of patients in
experimental and control groups, age, UAP diagnostic
criteria, intervention, treatment duration, and outcome
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bias in the included studies using criteria recommended in
the Cochrane Handbook for Systematic Reviews of In-
terventions, version 5.1.0. This risk was judged as high for
studies that met all criteria, unclear for studies with
insufficient information for judgment, and low for studies
that met none of the criteria.15
Statistical analysis
Dichotomous data were analyzed using relative risks (RRs)
and continuous variables were analyzed using weighted
mean differences (WMDs); effect sizeswere indicated by 95%
confidence intervals (CIs). Statistical heterogeneity was
measured using the I2 statistic. Fixed-effect models were
applied if there was no significant heterogeneity across
studies (I2 < 50%); otherwise, random-effects models were
applied. All P-values were two-tailed, and the threshold for
statistical significance was set at 0.05. Cochrane Collabora-
tion software (RevMan 5.2, Copenhagen, Denmark) was used
to perform statistical analyses. There is no registered pro-
tocol for the present meta-analysis.Fig. 1 Flow chart of studResults
Based on our inclusion criteria, we identified 1098 potential
studies from our initial search and excluded 644 trials for
duplicated publications. Subsequently, 108 potential trials
were identified, 97 of which were excluded for specific
reasons (Fig. 1). Eventually, only 11 RCTs9e13,16e21 met our
inclusion criteria.Characteristics of the included studies
The characteristics of the 11 included RCTs are listed in
Table 1. The RCTs collectively involved 686 patients and
were published between 2002 and 2014. All patients were
residents of the People’s Republic of China. Of this total,
352 patients received ABCD Chinese medicine alone or in
combination (experimental group). The treatment course
ranged from 2 to 4 weeks, and RAS and ECG improvement
were the most common outcome measures. Serum hs-CRP
and blood lipid levels were the most commonly measured
laboratory indices.y search and selection.
Table 1 Characteristics of the trials included in this meta-analysis.
Study Sample
size T/C
Mean age T/C Diagnosis
standard
Course
(week)
Experimental group Control group Outcome
measures
Feng et al.,
2014
30/31 61.9/61.4 2007
CDTGUANSTEMI
4 Xiongshao
capsule þ Huanglian
capsule þ CD
Xiongshao
capsule þ CD
hs-CRP BL
Pei et al.,
2012
32/32 61.94/60.36 2007
CDTGUANSTEMI
3 Guizhi fuling
decoction þ Huanglian
jiedu decoction þ CD
CD RAS BL hs-CRP
FAA DAA
Zhang et al.,
2004
45/30 58.89/58.77 1979
ISFC/WHO
4 Tongmai jiedu decoction CD RAS ECG
Zhao et al.,
2007
42/38 52.52/50.24 2000
CDTGUANSTEMI
2 Huayu jiedu decoction CD RAS CRP SRRN
TNFa
He et al.,
2007
30/30 61.96/62.93 1979 ISFC/WHO 4 Huoxue jiedu
decoction þ CD
CD RAS ECG hs-CRP
Chen et al.,
2009
30/31 61.24/61.84 2007
CDTGUANSTEMI
2 Xiongshao
capsule þ Huanglian
capsule þ CD
Xiongshao
capsule þ CD
RAS ECG hs-CRP
BL AE
Pan et al.,
2010
38/38 58.23/57.69 GCRNDTCM 4 Qingre jiedu huoxue
decoction þ CD
CD RAS ECG hs-CRP
Gao et al.,
2014
33/32 65.9/67.2 GCRNDTCM 2 Quyu jiedu
decoction þ CD
CD RAS ECG hs-CRP
FIB
Zeng et al.,
2009
28/25 58.2/56.4 2000
CDTGUANSTEMI
2 Xuebijing injection þ CD CD BL TNFa FIB
Peng et al.,
2012
20/20 61/60.6 2007
CDTGUANSTEMI
2 Shuxin tongbi
decoction þ CD
CD RAS ECG
Wang et al.,
2002
20/23 63.5/64.8 2000
CDTGUANSTEMI
2 Huangqi injection þ Luotai
injection þ Jiedu huxin
capsule þ CD
CD CD62P vWF
CDTGUANSTEMI: Chinese diagnosis and treatment guidelines of unstable angina and non-ST segment elevation myocardial infarction;
GCRNDTCM: Guidelines of clinical research of new drugs of traditional Chinese medicine; ISFC/WHO: International Society and Feder-
ation of Cardiology/World Health Organization; hs-CRP: high-sensitivity C-reactive protein; BL: blood lipid; FAA: frequency of angina
attacks; DAA: duration of angina attack; RAS: reduction of angina symptoms; ECG: electrocardiogram; SRRN: stopping or reducing rate of
nitroglycerin; TNFa: tumor necrosis factor alpha; AE: adverse event; FIB: fibrinogen; T/C: treatment/control; CD62P: P-selectin protein;
vWF: von Willebrand factor; CD: conventional drugs.
74 Y. Zhang et al.Quality assessment of the included studies
All 11 RCTs mentioned the term randomization, but only
three described it in detail. None mentioned allocation
concealment or intention-to-treat analysis. Because not all
the trial protocols were accessible, the extent of selective
reporting was generally unclear (Figs. 2 and 3).Fig. 2 Risk of bias graph: review authors’ judgments about each
studies.Effects of interventions
RAS
RAS was evaluated in eight studies including 529 patients,
with 274 in the experimental group and 255 in the control
group. A random-effects model was used to analyze the
data according to heterogeneity testing (I2 Z 78%,risk of bias item presented as percentages across all included
Fig. 3 Risk of bias summary: review authors’ judgments about each risk of bias item for each included study. þ: Low risk of bias;
: High risk of bias; ?: Unclear risk of bias.
Traditional Chinese medicine in unstable angina pectoris 75P < .0001). Overall, the outcomes showed a statistically
significant difference in favor of the experimental group
(RR, 1.23; 95% CI, 1.05e1.44; P Z .001; Fig. 4). This indi-
cated that ABCD Chinese medicine exhibited superior
effectiveness in relieving angina symptoms.
ECG improvement
Six studies including 377 patients, with 196 in the experi-
mental group and 181 in the control group, analyzed ECG
improvement. Data were analyzed using a random-effects
model according to heterogeneity testing (I2 Z 87%,
P < .00001). Overall, the results showed that ABCD Chinese
medicine produced no significant ECG improvement
compared with control interventions (RR, 1.21; 95% CI,
0.91e1.62; P Z .19; Fig. 5).
Serum blood lipid levels
Four studies involving 247 patients, with 124 in the exper-
imental group and 123 in the control group, reported serum
blood lipid levels, including total cholesterol (TC), triglyc-
eride (TG), high-density lipoprotein cholesterol (HDL-C),
and low-density lipoprotein cholesterol (LDL-C). The results
indicated that ABCD Chinese medicine significantly loweredFig. 4 Forest plots for reducTC, TG, and LDL-C levels and increased HDL-C levels
compared with control interventions. The details are shown
in Table 2 and Fig. 6.
Anti-inflammatory effects
Five studies analyzed serum hs-CRP levels. After pooling
these trials, we observed that ABCD Chinese medicine
significantly decreased hs-CRP levels (WMD, 0.86; 95% CI,
1.14w 0.57; P< .00001). Data concerning tumor necrosis
factor alpha (TNFa) andCRPwere extracted fromtwo trials; a
summary of these indices is shown in Table 3 and Fig. 7.
Overall, we noted that ABCD Chinese medicine exhibited
better anti-inflammatory effectswith regard to serumhs-CRP
and TNFa levels compared with control interventions.
Anticoagulant effects
Plasma fibrinogen (FIB) levels were measured in two trials.
ABCD Chinese medicine significantly decreased FIB levels
(WMD, 0.58; 95% CI, 0.95w 0.21; P Z .002; Fig. 8).
Furthermore, one trial claimed that CD62p (P-selectin
protein) decreased from 8.69  2.11% to 5.40  1.46% with
ABCD Chinese medicine, while vWF decreased from
142.47  17.06% to 110.58  18.57%.tion of angina symptoms.
Fig. 5 Forest plots for ECG improvement.
Table 2 Summary of the weighted mean differences (WMDs) for blood lipid levels.
Outcomes Included studies WMD and 95% CI P-value Heterogeneity P-value for heterogeneity
TC (mmol/L) 11,14,15,17 0.20 [0.38, 0.02] 0.03 7% 0.36
TG (mmol/L) 11,14,15,17 0.22 [0.40, 0.04] 0.02 0% 1.00
LDL-C (mmol/L) 11,14,15,17 0.20 [0.36, 0.04] 0.01 4% 0.37
HDL-C (mmol/L) 11,14,15,17 0.07 [0.02, 0.11] 0.003 18% 0.30
CI: confidence interval; TC: total cholesterol; TG: triglyceride; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipo-
protein cholesterol.
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One trial reported the frequency of angina attacks (FAA)
and the total duration of angina attacks in 24 h (DAA) as
outcomes. Compared with control interventions, ABCD
Chinese medicine significantly decreased FAA (3.50  3.20
times/week to 6.22  3.87 times/week; P < .05) and DAA
(10.68  8.42 min/d to 27.91  14.70 min/d; P < .05).
Another trial reported the stopping or reducing rate of
nitroglycerin (SRRN) as an outcome; this was 90.48% and
68.42% in the experimental and control groups,
respectively.
Publication bias
Because of the insufficient number of included trials, we
did not use a funnel plot to detect publication bias.
Adverse effects
Only one trial reported adverse events in the form of mild
diarrhea in four patients in the experimental group that
disappeared after dose reduction. No severe adverse events
were reported.
Discussion
This systematic review analyzed evidence for 686 patients
included in 11 RCTs. The pooled results showed significant
RAS and superior anti-inflammatory, anticoagulant, and
lipid-lowering effects for ABCD Chinese medicine. To the
best of our knowledge, the present meta-analysis is the first
to evaluate the efficacy of ABCD Chinese medicine for UAP.Systemic markers of inflammation have been found in
patients with UAP. Disruption of culprit coronary stenosis
may cause a greater inflammatory response in patients with
unstable angina than in those with stable angina. Our study
showed that ABCD Chinese medicine decreased TNFa and
hs-CRP more than did conventional therapy. Therefore,
anti-inflammation might be one of the mechanisms by
which ABCD Chinese medicine exerted its protective effect
on UAP patients.
Recently, several meta-analyses on herbs, TCM
formulae, or Chinese patent medicines for angina pectoris
have been published. One study suggested that combina-
tion therapy with Xuefu Zhuyu decoction and conventional
drugs is more beneficial and effective in treating angina
pectoris compared with conventional drugs alone, and that
Xuefu Zhuyu decoction may be a better choice for the
treatment of stable angina pectoris (SAP),22 Another of
these meta-analyses indicated that Chinese patent medi-
cines could improve the survival of angina patients who
consumed Western medicines.23 Yet another systematic
review showed that compound salvia pellet, a Chinese
patent medicine, could relieve angina symptoms and
improve ECG results with few adverse effects.24 However,
neither these studies nor the present study can draw
definitive conclusions from the results because of the
following limitations.
First, most of the included studies provided insufficient
information about randomization procedures. Unsuccessful
randomization can lead to selection bias while allocating
interventions to participants.25 Second, none of the studies
were double-blind trials, even though blinding is very
important to ensure that patients have equivalent experi-
ences and that each patient has an equal chance of being
allocated to one or other of the conditions during the
Fig. 6 Forest plots for blood lipid. A: triglyceride; B: total cholesterol; C: low-density lipoprotein cholesterol; D: high-density
lipoprotein cholesterol.
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mentioned allocation concealment, withdrawal, or dropout
events. Fourth, although UAP is a lifelong disease, all
included trials featured short-term outcomes because of
the absence of follow-ups. This could also explain why the
incidence of adverse events was too low for safety evalu-
ations. Fifth, as described previously, we only searched
Chinese and English databases. However, herbal medicines
are also used commonly in other Asian countries such asTable 3 Summary of the weighted mean differences (WMDs) fo
Outcomes Included studies WMD and 95% CI
hs-CRP (mg/L) 10,11,13,14,15 0.86 [1.14, 0.57]
TNFa (ng/mL) 9,17 5.05 [7.51, 2.59]
CRP (mg/L) 9,10 3.53 [12.35, 5.30]
CI: confidence interval; hs-CRP: high-sensitivity C-reactive protein; TJapan and Korea. This may have led to a potential selection
bias, thus limiting external generalization of evidence.
In addition to quality limitations, the estimates of some
outcomes were limited by small sample sizes. The sample
size in all trials was <100 and could have influenced the
precision of estimates. Even so, we believe this meta-
analysis is of great importance because it at least provides
moderate evidence regarding the effectiveness of ABCD
Chinese medicine for UAP in clinical settings. Furtherr inflammatory factors.
P-value Heterogeneity P-value for heterogeneity
<0.00001 2% 0.39
<0.0001 99% <0.00001
0.43 99% <0.00001
NFa: tumor necrosis factor alpha; CRP: C-reactive protein.
Fig. 7 Forest plots for inflammatory factors. A: high-sensitivity C-reactive protein; B: tumor necrosis factor alpha; C: C-reactive
protein.
Fig. 8 Forest plots for fibrinogen.
78 Y. Zhang et al.studies should explore the mechanisms of action of ABCD
Chinese medicine in UAP patients.
Conclusions
The present study provides preliminary evidence that sup-
ports the continued use of ABCD Chinese medicine as a
potentially optimistic and reliable intervention for UAP.
Further work is needed to improve understanding of this
treatment using rigorously designed, multicenter, large-
scale clinical trials that investigate the effectiveness and
safety of ABCD Chinese medicine for UAP.
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